Oncolytics Biotech

Pelareorep replicates in cancer cells, triggering immune responses that may enhance oncology treatments.

Oncolytics is researching pelareorep’s potential in breast, gastrointestinal, hematologic, and other cancers.

Oncolytics Biotech seeks to hire motivated professionals.

Angela Holtham held financial roles at Nabisco Inc. for 19 years, rising to Senior Vice President and Chief Financial Officer. She later served as Vice President, Finance and CFO at Toronto’s Hospital for Sick Children from 2002 to 2010.

Dr. Bernd Seizinger serves on the boards of Vaccibody, Oxford BioTherapeutics, Aprea, CryptoMedix, and BioInvent. He previously led GPC Biotech as President & CEO and held roles at Bristol-Myers Squibb and Genome Therapeutics.

Deborah Brown is a Management Consultant and Managing Partner at Accelera Canada, a firm supporting biopharma ventures in the United States and Europe. She previously held senior roles at EMD Serono, including Executive Vice President of Neuroimmunology for its U.S. operations.

James Parsons has over 20 years of executive experience in life sciences. He served as CFO of Trillium Therapeutics Inc. from 2011 until its acquisition by Pfizer in 2021. Before Trillium, he led Empar Management and previously held finance roles at other companies.

The page highlights Oncolytics’ team of scientists, cancer researchers, and clinicians.

The page provides contact information for inquiries about Oncolytics Biotech and its immunotherapy pelareorep.

Oncolytics is developing pelareorep, a unique immunotherapy with the power to awaken the immune system and unlock its antitumor potential across cancer types